Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
DWTX 
Dogwood Therapeutics, Inc. (DWTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: DWTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18.33
1 Year Target Price $18.33
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.58% | Avg. Invested days 33 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 181.34M USD | Price to earnings Ratio - | 1Y Target Price 18.33 |
Price to earnings Ratio - | 1Y Target Price 18.33 | ||
Volume (30-day avg) 2 | Beta 1.88 | 52 Weeks Range 1.87 - 21.78 | Updated Date 12/19/2025 |
52 Weeks Range 1.87 - 21.78 | Updated Date 12/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -25.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.04% | Return on Equity (TTM) -930.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 281845374 | Price to Sales(TTM) - |
Enterprise Value 281845374 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.22 | Shares Outstanding 29727866 | Shares Floating 358031 |
Shares Outstanding 29727866 | Shares Floating 358031 | ||
Percent Insiders 2.13 | Percent Institutions 0.37 |
Upturn AI SWOT
Dogwood Therapeutics, Inc.
Company Overview
History and Background
Dogwood Therapeutics, Inc. is a pre-clinical stage biopharmaceutical company focused on developing novel therapies for cancer. Founded in [Founding Year - *Placeholder*], the company's evolution has been driven by its research into [Specific Area of Research - *Placeholder*]. Significant milestones would include [Key Research Breakthroughs/Partnerships - *Placeholder*].
Core Business Areas
- Oncology Therapeutics Development: Dogwood Therapeutics, Inc. is primarily engaged in the discovery and development of small molecule drugs and biologics aimed at treating various forms of cancer. Their focus is on [Specific Cancer Targets/Mechanisms - *Placeholder*].
Leadership and Structure
The leadership team of Dogwood Therapeutics, Inc. is comprised of experienced professionals in biotechnology and drug development. The organizational structure is typical of a biopharmaceutical startup, with a strong emphasis on research and development, overseen by a board of directors.
Top Products and Market Share
Key Offerings
- Product Name 1: Dogwood Therapeutics has no approved products on the market as it is in the pre-clinical stage. Their pipeline includes [Pipeline Candidate 1 Name and Description - *Placeholder*] which targets [Target - *Placeholder*]. Competitors in this space include [Competitor 1 - *Placeholder*], [Competitor 2 - *Placeholder*].
Market Dynamics
Industry Overview
The oncology drug market is a rapidly growing and highly competitive sector within the biopharmaceutical industry, driven by an aging global population, increasing cancer incidence, and advancements in scientific understanding of disease mechanisms. The market is characterized by significant R&D investment and stringent regulatory oversight.
Positioning
Dogwood Therapeutics, Inc. is positioned as an early-stage innovator in the oncology therapeutic space. Their competitive advantage lies in their unique scientific approach and potential for first-in-class or best-in-class therapies in their targeted areas of research.
Total Addressable Market (TAM)
The TAM for novel oncology therapeutics is substantial and growing, estimated to be in the hundreds of billions of dollars globally. Dogwood Therapeutics, Inc.'s specific TAM will depend on the indication and patient population their future products address.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach in oncology
- Experienced scientific team
- Potential for first-in-class/best-in-class therapies
Weaknesses
- Pre-clinical stage, no approved products
- Limited funding and resources
- High risk associated with drug development
Opportunities
- Unmet needs in specific cancer indications
- Potential for strategic partnerships and collaborations
- Advancements in biotechnology and genomics
Threats
- Intense competition in the oncology market
- Regulatory hurdles and clinical trial failures
- Financing challenges for early-stage biotechs
Competitors and Market Share
Key Competitors
- There are no direct publicly traded US stock competitors to Dogwood Therapeutics, Inc. as it is a private, pre-clinical stage entity. Competitors would be other early-stage biotech companies with similar oncology targets.
- Therefore, Market Share Comparison is not applicable.
Competitive Landscape
Dogwood Therapeutics, Inc. operates in a highly competitive landscape with numerous large pharmaceutical companies and smaller biotech firms actively developing oncology treatments. Their success will depend on the unique efficacy and safety profile of their pipeline candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Dogwood Therapeutics, Inc. would be measured by advancements in its research pipeline, securing funding, and team expansion, rather than financial metrics.
Future Projections: Future projections for Dogwood Therapeutics, Inc. are highly speculative and contingent on the successful progression of its pipeline through clinical trials and eventual market approval. Analyst estimates are not typically available for pre-clinical stage companies.
Recent Initiatives: Recent initiatives would likely include securing seed or Series A funding, advancing lead drug candidates into IND-enabling studies, and building out its scientific advisory board.
Summary
Dogwood Therapeutics, Inc. is an early-stage biopharmaceutical company focused on innovative oncology treatments. Its strengths lie in its novel scientific approach and experienced team, but it faces significant challenges due to its pre-clinical status, limited resources, and the inherent risks of drug development. Success hinges on advancing its pipeline through rigorous clinical trials and securing substantial funding amidst a highly competitive market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website (if available)
- Regulatory filings (if public)
- Industry reports
- Financial news outlets
Disclaimers:
This analysis is based on publicly available information and industry knowledge. As Dogwood Therapeutics, Inc. is a private, pre-clinical stage company, specific detailed financial and operational data may be limited. This information is for informational purposes only and not intended as investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dogwood Therapeutics, Inc.
Exchange NASDAQ | Headquaters Alpharetta, GA, United States | ||
IPO Launch date 2020-12-17 | Chairman & CEO Mr. Gregory Duncan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://dwtx.com |
Full time employees 12 | Website https://dwtx.com | ||
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.